Related Links
Alpha-1 as Seen
on PBS
Watch the PBS show about Alpha-1.
eLearning Program
View our eLearning Program to learn more about Alpha-1.
ARALAST NP Therapy
ARALAST NP therapy is a chronic augmentation therapy for patients with congenital alpha-1 antitrypsin (AAT) deficiency* who have been diagnosed with clinically evident emphysema.
* Also known as Alpha-1, AAT Deficiency, AATD, A1-PI deficiency, alpha-1 proteinase deficiency, A1AD, or hereditary or genetic emphysema.
How ARALAST NP Therapy Works
ARALAST NP therapy is an augmentation therapy that raises AAT levels in your blood and lungs.
Learn More
Getting Started on ARALAST NP Therapy
Starting augmentation therapy is easier than you might think.
Learn More
ARALAST NP AATmosphere Program
The ARALAST NP AATmosphere program is an encompassing environment designed to help you manage Alpha-1 by providing you with continuous online and phone support.
Learn More
ARALAST NP Sample
Baxter is offering Alpha-1 patients (who have not previously used ARALAST NP therapy) and their physicians the opportunity to receive a complimentary two-week sample supply of the product.
Learn More
ARALAST NP Therapy Tolerability
ARALAST NP Therapy Safety Profile
ARALAST NP Therapy Convenience
ARALAST NP [Alpha1-Proteinase Inhibitor (Human)]
ARALAST NP is indicated for chronic augmentation therapy in patients having congenital deficiency of A1-PI with clinically evident emphysema. ARALAST NP is not indicated as therapy for lung disease patients in whom congenital A1-PI deficiency has not been established.
The effect of augmentation therapy with ARALAST NP on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials.
Important Risk Information for ARALAST NP
ARALAST NP is contraindicated in IgA deficient patients with antibodies against IgA, due to the risk of severe hypersensitivity.
ARALAST NP is derived from pooled human plasma. It may carry a risk of transmitting infectious agents, e.g., viruses and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
The recommended rate of administration (≤ 0.08mL/kg/min) should be closely followed and vital signs monitored continuously. If anaphylactic or severe anaphylactic reactions occur, the infusion should be discontinued immediately.
Safety and effectiveness in patients over age 65 years of age have not been established.
ARALAST NP should be administered at room temperature within three (3) hours after reconstitution and should be administered alone, without mixing with other agents or diluting solutions.
The safety of ARALAST NP was evaluated with ARALAST in a crossover clinical PK comparability study. The most common adverse events deemed related to ARALAST NP included headache and musculoskeletal discomfort. No serious adverse reactions or deaths were reported in the study. In the ARALAST pivotal study, the most common adverse events were headache and somnolence.
Please see ARALAST NP Prescribing Information for full prescribing details.
